Insider · CIK 0001826323
Marella Thorell
Files at MCRB (Seres Therapeutics, Inc.), EPIX (ESSA Pharma Inc.). First filing -, latest -.
In brief
Marella Thorell files SEC Form 4 as director and officer at MCRB (Seres Therapeutics, Inc.), and also at EPIX (ESSA Pharma Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Marella Thorell has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | MCRB Seres Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 10, 2026 |
| Mar 4, 2026 | MCRB Seres Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Mar 6, 2026 |
| Oct 9, 2025 | EPIX ESSA Pharma Inc. | DDisposition to issuer Common Shares | -2,881 | - | - | 0 | Oct 15, 2025 |
Questions about Marella Thorell
Answered from the filings on this page, as of the latest one.
Is Marella Thorell buying or selling?
Marella Thorell has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Marella Thorell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Marella Thorell has 0.
Where does Marella Thorell file Form 4?
Marella Thorell has filed Form 4 at MCRB (Seres Therapeutics, Inc.) as See Remarks; EPIX (ESSA Pharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.